LILLY LAUNCHES BIOTECH APP STORE WITH $7.3B

The pharmaceutical giant is positioning itself as an AI infrastructure provider for drug discovery. The initiative represents a shift toward collaborative AI tools, with Lilly partnering with smaller biotechs to accelerate research processes. The data center deployment signals Lilly's commitment to computational drug development. The Blackwell chip infrastructure will power the app marketplace, offering biotech companies access to AI-driven discovery platforms without requiring massive individual investments in hardware. This move aligns with broader industry trends as pharma companies increasingly adopt AI for early-stage research. By monetizing its computational capacity through an app ecosystem, Lilly creates a new revenue stream while positioning itself at the center of biotech innovation. The company's substantial cash allocation underscores confidence in AI's role in future drug development and suggests Lilly expects long-term returns from infrastructure investment rather than immediate drug launches.